All In Biotech

Drug Trial Radar · NCT07114861

The KN510713 Study in Combination With mFOLFIRINOX

An Open-label, Dose-finding and Dose-expansion, Phase I/IIa Clinical Trial to Evaluate the Safety and Efficacy of KN510713 in Combination With mFOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Dec 16, 2025

Primary completion

Sep 22, 2028

Study completion Oct 22, 2028

Sponsor

Lead sponsor
New Cancer Cure-Bio Co.,Ltd.Industry
Sponsor type
Industry
First posted
Aug 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the safety and efficacy of KN510713 in combination with mFOLFIRINOX in patients with locally advanced or metastatic pancreatic cancer. The study will be conducted in two parts: Part 1 (Dose-finding) and Part 2 (Dose expansion).

Conditions

  • Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

  • Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOXDrug

    KN510 120mg/day + KN713 90mg/day: once daily in 14-day (2-week) cycles. mFOLFIRINOX: Treatment is repeated every 2 weeks

  • Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOXDrug

    KN510 120mg/day + KN713 120mg/day: once daily in 14-day (2-week) cycles. mFOLFIRINOX: Treatment is repeated every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of occurrences, affected subjects with adverse events.Time frame: Through study completion, an average of 12 months
  2. The frequency and percentage of Dose-Limiting ToxicitysTime frame: 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center

    Goyang-si, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.